Continuous UVA for Keratoconus
This trial found that the accelerated crosslinking method was effective in reducing the progression of keratoconus.
- Corneal Ectasia
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
How many people will be given this medication as part of the research?
"That is correct, the information available on clinicaltrials.gov indicates that the trial is currently underway and looking for 170 individuals from 1 locations."
Are new patients needed for this ongoing research project?
"The clinicaltrials.gov website indicates that the trial is still looking for subjects. According to the site, the 170 patients are needed at a single location. The trial was posted on 7/30/2021 and was last updated 9/15/2021."
Has the FDA cleared Pulsed UVA for public use?
"There is some evidence to support Pulsed UVA's efficacy, as this is a Phase 3 trial. Furthermore, there is enough safety data from multiple rounds of testing to give it a safety score of 3."
What are some other examples of research that has been done using Pulsed UVA?
"Pulsed UVA is being trialed in 20 different studies at the moment, 11 of which are in the 3rd stage of clinical trials. The majority of research centres for Pulsed UVA are located in San Francisco, but there are a total of 47 sites running these tests."